Compare Abbott Laboratories (ABT) vs Apollo Global Management Ord Shs (APO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Apollo Global Management Ord Shs — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Apollo Global Management Ord Shs trades at $118.29 (market cap $68.80B). The key difference: Abbott Laboratories is far larger — about 2.4× Apollo Global Management Ord Shs's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | APO | |
|---|---|---|
Market Cap | $166.94B | $68.80B |
Sector | Health | Financials |
52-Week High | $136.62 | $156.05 |
52-Week Low | $82.57 | $100.30 |
Enterprise Value | $193.69B | -$168.77B |
Dividend Yield | 2.63% | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Apollo Global Management (APO) trades at $119.33, up 0.61% with a bearish technical signal despite strong analyst consensus. The company reported Q1 2026 EPS of $1.94, beating expectations, and maintains a 95.15% gross margin. Recent news highlights liquidity pressures in private credit funds, with Apollo capping withdrawals from its $25 billion Apollo Debt Solutions fund after 17% redemption requests in Q2 2026.
Outlook remains mixed: strong fee-generating AUM growth and dividend increases support bullish analyst targets averaging $149.71, but near-term risks include private credit liquidity concerns and multiple law firm investigations. The stock offers 25% upside to consensus target if liquidity pressures ease and earnings meet guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →
